Clinical trial
Intermittent Liposomal Amphotericin B Primary Prophylaxis
NCT00451711 · Bayside Health, Other · Unknown status
Key facts
| NCT number | NCT00451711 |
|---|---|
| Title | Intermittent Liposomal Amphotericin B Primary Prophylaxis |
| Official title | A Randomised, Stratified, Open Label, Phase II Pilot Study on the Safety of a Daily, Intermittent, or Weekly Administration of 1, 3 or 10mg/kg of AmBisome® in Antifungal Primary Prophylaxis of High-Risk Patients With Acute Myeloid Leukaemia |
| Lead sponsor | Bayside Health, Other |
| Collaborators | Gilead Sciences Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Liposomal amphotericin B |
| Enrollment | 60 |
| Start date | May 1, 2007 |
| Completion | Oct 1, 2014 |
| First posted | Mar 23, 2007 |
| Last update posted | Dec 16, 2013 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: